Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 417-420

  Bassetti, Matteo ^a   Repetto, E ^a   Righi, E ^a   Boni, S ^b   Diverio, M ^c   Molinari, M P ^a   Mussap, M ^a   Artioli, S ^b   Ansaldi, F ^a   Durando, P ^a   Orengo, G ^a   Bobbio Pallavicini, F ^a   Viscoli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Felettino Hospital   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Bacteraemia; ICU; Multiresistant; Nephrotoxicity; Ventilator associated pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BELLON; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PROGNOSIS; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; COLISTIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME;

EID: 38349181470     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm509     Document Type: Article

References (14)

1. Basustaoglu AC, Kiss O, Sacilik SC et al. Epidemiological characterization of hospital acquired A. baumannii isolates from 1500 bed teaching hospital by pñenotypic and genotypic methods. J Hosp Infect 2001; 47: 246-9.
2. Forster DH, Daschner FD. Acinetobacter species as nosocomial pathogens. Eur J Clin Microbiol Infect Dis 1998; 17: 73-7.
3. Gales AC, Jones RN, Forward KR et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas Maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the Sentry Antimicrobial Surveillance Program [1997-1999]. Clin Infect Dis 2001; 32 Suppl 2: 104-13.
4. Li J, Nation RL, Tumidge JD et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
5. Michalopoulos AS, Tsiodras S, Rellos K et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microb Infect 2005; 11: 115-21.
6. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
7. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: The significance of co-administration of rifampicin. Int J Antimicrob Agents 2007; 29: 51-5.
8. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
9. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
10. Petrosillo N, Chinello P, Proietti MF et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: Clinical outcome and adverse events. Clin Microbiol Infect 2005; 11: 682-3.
11. Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-8.
12. Levin AS, Barone AA, Pengo J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
13. Gamacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 3: 1111-8.
14. Kallel H, Hergafi L, Bahloul M et al. Safety, and efficacy of colistin compared with imipenem in the treatment of ventilator associated pneumonia a matched case-control study. Intensive Care Med 2007; 33: 1162-7.